TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Burning Rock Biotech ( (BNR) ) is now available.
Burning Rock Biotech Limited announced that its 2025 Annual General Meeting (AGM) will be held on December 23, 2025, in Shanghai. The AGM will address proposals such as the ratification of Ernst & Young Hua Ming LLP as auditors, the re-election of directors Feng Deng and Licen Lisa Xu, and authorizing directors to implement necessary actions. The board supports these proposals and encourages shareholders to vote in favor. The company has also filed its annual report for the year ended December 31, 2024, with the SEC.
The most recent analyst rating on (BNR) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Burning Rock Biotech stock, see the BNR Stock Forecast page.
Spark’s Take on BNR Stock
According to Spark, TipRanks’ AI Analyst, BNR is a Neutral.
Burning Rock Biotech’s overall stock score is driven primarily by its strong technical momentum, despite significant financial challenges. The company’s stable balance sheet and strategic focus on in-hospital services and R&D provide some optimism. However, negative cash flows and valuation concerns due to net losses weigh on the score.
To see Spark’s full report on BNR stock, click here.
More about Burning Rock Biotech
Burning Rock Biotech Limited, listed on NASDAQ as BNR, is a company dedicated to the application of next generation sequencing (NGS) technology in precision oncology. The company offers NGS-based therapy selection testing for late-stage cancer patients and is advancing cancer early detection from research and development into clinical validation.
Average Trading Volume: 35,746
Technical Sentiment Signal: Buy
Current Market Cap: $232.5M
Find detailed analytics on BNR stock on TipRanks’ Stock Analysis page.